New immune booster shows promise in early breast cancer trial
NCT ID NCT02950259
First seen Jan 03, 2026 · Last updated Jun 16, 2026 · Updated 24 times
Summary
This early-phase study tested whether an experimental immune therapy called IRX-2 is safe when given before standard chemotherapy in 16 people with early-stage breast cancer, including those with triple-negative breast cancer. The main goal was to see if IRX-2 caused any delays in surgery. Researchers also looked at how the treatment affected immune cells in the tumor. The study was completed and focused on safety and immune response, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.